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ABSTRACT
Objective: The present study aimed to evaluate the ameliorative eﬀect of low-dose ethanol
(Eth) on amnesia induced by a brief seizure model and the role of N-methyl D-aspartate
(NMDA) signaling in this event.
Materials and Methods: Four groups of rats (total number = 36; n = 9, each group) were
used: control, Eth (0.5 g/kg/i.p.), pentylenetetrazole (PTZ) (60 mg/kg/i.p.), and Eth+PTZ. Eth
was administered for 6 days before the single injection of PTZ, at minute dose that cannot
induce memory impairment. The consequences of Eth pretreatment, coadministered with
PTZ, were studied in an inhibitory avoidance (IA) memory model. The PTZ was injected 30
min prior to the IA memory test. Thereafter, locomotion, liver enzymes, and the Real-time PCR
for NR1 subunit of NMDA receptor were studied. The statistical analyses were performed
using the parametric/nonparametric ANOVA and the post-hoc tests.
Results: Our ﬁndings revealed that Eth pretreatment signiﬁcantly improved the IA memory
impairment induced by PTZ (P < 0.001), and indicated no change in locomotion and serum
ALT, but signiﬁcantly diﬀered for AST between the PTZ and PTZ groups (P = < 0.05). The Real-
time PCR results indicate the decreased NR1 mRNA expression in Eth and PTZ groups and the
increased NR1 mRNA expression in Eth+PTZ group, compared to the control group
(P < 0.001); however, the NR1 mRNA expression was increased in the Eth+PTZ group,
compared to PTZ group (P < 0.001).
Conclusion: The present study provides evidence that the low-dose Eth can improve the
amnesia induced by a brief seizure model presumably via NMDA signaling in a rat.
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Previous studies have reported that high ethanol
(Eth) intake induces cognitive deﬁcit [1] and neuro-
nal injury [2]. Nevertheless, increasing evidence sug-
gests that low to moderate Eth intake may protect
against the harmful eﬀects of cerebral ischemia [3]
and age-dependent cognitive disorders, for example,
Alzheimer’s disease [4], via the Eth preconditioning
(EtOH-PC) mechanism [5]. The EtOH-PC is deﬁned
as a process in which the nervous system [6] survives
the degenerative impacts of an insult at low to mod-
erate doses of Eth. In addition, several studies illu-
strated that the moderate dose of Eth shortly before
brain ischemia ameliorates the postischemic beha-
vioral disorders and degenerative process in the hip-
pocampus [6]. Most nervous system stimulating
agents, including Eth, have a selective enhancing
eﬀect over the motor system [7] and alter the loco-
motor activity [8].
Pentylenetetrazole (PTZ), as a gamma aminobutyric
acid (GABA) receptor antagonist, exerts its eﬀect via the
inhibition of the GABAa chloride channel and is
routinely used to induce convulsion and epilepsy in
the experimental animal models [9]. It has been sug-
gested that the convulsive eﬀect of PTZ is observed even
following its single-dose administration [6], both via the
inhibition of GABA and the induction of glutamate
excitotoxicity [10]. As a result, the ﬁndings from the
nervous system studies indicate that PTZ also causes
neuronal damage [11].
From a molecular perspective, the available evi-
dence supports the fact that on preconditioning, Eth
interacts with the excitatory neurotransmitter,
N-methyl D-aspartate (NMDA) receptor [12], as the
main molecular substrate for neurotoxicity [13].
Since glutamate is a ubiquitous and potent excitatory
neurotransmitter, the Eth-induced inhibition of
NMDA receptor is presumed to underlie the acute
behavioral eﬀects of Eth, that is, motor impairment
[14]. Both short- [15] and long term [16] Eth intake
cause NMDA-induced responses mediated by NR1
subunit of the NMDA receptor. Moreover, meman-
tine inhibits the Eth-induced NMDA receptor upre-
gulation in rat hippocampal neurons [17].
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Herein, considering few contradictory ﬁndings
about the eﬀect of low-dose Eth on memory mediated
by NR1 subunit of NMDA receptors [18], to the best
of our knowledge, no study has evaluated the eﬀect of
low-dose Eth on PTZ-induced memory impairment
to date. Under these conditions, the inhibitory avoid-
ance (IA) memory, locomotor activity, and the liver
biochemical markers for injury were evaluated.
Moreover, considering the importance of NR1 in
memory impairment induced by Eth (as aforemen-
tioned), in order to provide a better link between the
mechanisms involved, the role of the mRNA expres-
sion of NR1, as the main subunit of NMDA [18] in
that event was studied.
Material and methods
Animals and housing conditions
In the present study, Wistar rats purchased from the
Pasteur Institute (Tehran, Iran) were used in four
groups (n= 9): control, Eth (0.5 g/kg/i.p.), pentylene-
tetrazole (PTZ; 60 mg/kg/i.p.), and Eth+PTZ. Rats
(200–220 g) were housed four per cage and accli-
mated to the animal room at least 2 weeks prior to
the study initiation. Animals had free access to food
and water. Appropriate room temperature (22 ± 2°C),
humidity (50%), and light/dark cycle (12/12-h) were
maintained. All experimental procedures were in
accordance with the European Community Council
Directive (86/609/ECC). This project was registered
with the ethical code of IR.KAUMS.REC.1395.83in
the Ethics Committee of Kashan University of
Medical Sciences (KAUMS).
Chemicals
The drugs used were PTZ (Tocris, England) and Eth
(Jahan Teb Arak, Iran). Eth was stocked at 0.9%,
diluted in saline to yield the ﬁnal concentration of
0.5 g/kg, and was injected once per day as
a pretreatment for 6 days. The last dose of Eth was
injected the day before the training session. Following
the Eth pretreatment,a2 day IA memory test was
performed and the single dose PTZ (60 mg/kg) was
administered before the IA retrieval session on
the second day of the IA test. All drugs were admi-
nistered intraperitoneally (i.p.) and were freshly pre-
pared in saline each day.
Brief seizure assessment
Approximately 2 min following the PTZ injection,
the animals were monitored in isolated Plexiglas
cages for 10 min. The convulsion rating was done
according to a 5-point scale, as reported previously
[19]: stage 0: no response; stage 1: ear and vibrissae
vibration; stage 2: convulsive waves along the trunk
axis; stage 3: myoclonic seizures with rearing; stage 4:
clonic-tonic seizures with no falling; and stage 5:
generalized tonic extension. The average seizure
score 3 in all PTZ received animals was considered
as a criterion for inclusion into the study.
IA model
The IA setup was a double-chamber box (20 × 20 ×
30 cm) with a guillotine door isolating the dark and
light chambers. The ﬂoor of the chambers was cov-
ered with stainless steel grids for delivering electric
shock (50 Hz, 3 s, 1 mA) by a constant current
isolating stimulator (MazeRouter, Tabriz, Iran).
Behavioral procedures
Habituationwas done for 30min prior to the experiment.
About 5 s after the animal was placed in the light cham-
ber, the guillotine door was lifted to allow the animal to
enter into the dark chamber. When the animal entered
the dark chamber, the door was closed. Thereafter, the
animal was returned to its original cage. During the
training session (30 min later), after the animal was
placed again in the light chamber and allowed to enter
the dark chamber, a shockwas delivered to its feet. After 2
min, the procedure was repeated, and if the animal
refused to enter the dark chamber, a successful acquisi-
tion was recorded. During the test session (24 h later), no
shock was delivered. The pretest injection of the PTZwas
administered at 30 min interval with respect to memory
retrieval. The latency of entering the animal to the dark
chamber (cut-oﬀ 300 s) was recorded as a criterion for
memory. All behavioral experiments were performed
between 08 a.m. and 16 p.m.
Locomotion (open ﬁeld)
The open-ﬁeld setup was a dark-colored square appa-
ratus (50 cm-square and 30 cm-high) equipped with
a computerized CCD video tracking system and its
dedicated software (MazeRouter, Tabriz, Iran). Rats
were moved from their home cages to the open-ﬁeld
apparatus in the training session to allow acclimation
to their environmental conditions. Locomotor activ-
ity in the testing session was recorded as the distance
(cm) traveled in 5 min.
Serum AST/ALT measurements
To test the treatment-induced liver toxicity, the bio-
chemical markers of liver injury, aspartate transami-
nase (AST) and alanine transaminase (ALT), in the
serum were measured. On terminating the locomo-
tion test, blood samples were collected by a direct
cardiac puncture and after the clot formation (>30
min), the samples were centrifuged at 1500 rpm for
15 min at 4°C to obtain the serum. The serum sam-
ples were stored at – 80°C until the time of assay to
determine the serum levels of ALT and AST. The
ALT and AST were assessed using a kit (Pars
Azmoon, Iran) via spectrophotometry method.
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Estimation of NR1 mRNA expression
1. RNA Extraction
The total hippocampal RNA was extracted using an
RNeasy kit (SinaClon, Iran) and the total RNA yield
concentration was determined using a NanoDrop ND
3300 spectrophotometer (NanoDrop Technologies,
USA). The isolated total RNA was frozen at −80°C for
further processing.
2. Reverse Transcription
The high capacity cDNA reverse transcription kit
(TAKARA, IRAN) used included a transcription mix
(20 ml for each sample), comprising 0.6 mg total
RNA (10 ml), RT buﬀer (2 ml), dNTP (0.8 ml,
100 mM), RT random primers (2 ml), MultiScribe
TM Reverse Transcriptase (1 ml, 50 units/ml), and
nuclease-free water. Reactions were performed in the
thermal cycles (PEQ-LAB, DEUTDCHLAND) as step
I, 37°C for 15 min; step II, 85°C for 5 min; step III, 4°
C for 5 min; and step IV, inﬁnite. Simultaneously, the
transcription mixture was maintained at −20°C until
ampliﬁcation.
3. Quantitative Real-Time PCR
Using the following pair of primers, NR1-RTF, 5′-
GTCCACCAGACTGAAGATTGTGAC-3′; NR1- RTR,
5′-CTCCTCCTTGCATGTCCCA-3′; HPRT-RTF, 5′- G
CTCGAGATGTCATCAAGGAGA-3′′; HPRT- RTR 5’-
TCAGCGCTTTAATGTAATCCAGC-3′, the levels of
NR1, HPRT, and mRNA expression were determined.
Primers were used at the ﬁnal concentration of 300
nM. Real-time (RT-PCR) was performed in triplicate
using gene-speciﬁc primers and SYBR® GREEN PCR
Master Mix (BIOFACT, COREA). Oligonucleotide pri-
mers were designed using Primer Express software
(Applied Biosystems, USA). Hypoxanthine phosphori-
bosyltransferase (HPRT)was used as an internal control
for normalization. RT-PCR was performed on RT-PCR
Detection Systems (BIO-RAD, GERMANY) using
SYBR Green with the following thermal cycling proce-
dure: 1 cycle of 2 min at 50°C, 1 cycle of 10 min at 90°C,
40 cycles of 15 s at 95°C, and 1 min at 61°C.
Statistical analysis
After evaluating the normality of data via Kolmogorov–
Smirnov test, the behavioral data were analyzed using
the parametric/nonparametric analysis of variance
(ANOVA), the PCR data using the 2−ΔΔCT method
and HPRT as a reference gene [20]. A value of
P < 0.05 was considered as statistically signiﬁcant.
Results
Eﬀect of Eth pretreatment on PTZ-induced brief
seizure model in IA memory test
This experiment reveals the eﬀect of Eth pretreatment,
PTZ, and the coadministration of Eth+PTZ on IA
memory in the rat. The results of Kruskal–Wallis one-
way ANOVA on ranks revealed a signiﬁcant diﬀerence
in the IA memory between the groups[H(4) = 33.20,
P < 0.001]. Tukey’s post-hoc analysis indicated that PTZ
injection, 30 min prior to the test, signiﬁcantly reduced
the latency time of the animal to enter the dark com-
partment compared to the control group (P < 0.001).In
addition, further post-hoc analysis indicated that the
coadministration of Eth+PTZ, signiﬁcantly increased
the latency time of the animal to enter the dark com-
partment compared to the PTZ group (P < 0.001;
Figure 1).
Locomotor activity following the eﬀect of Eth
pretreatment on PTZ-induced brief seizure model
As presented in Figure 2, in terms of the distance
traveled (cm) in the open-ﬁeld apparatus, one-way
ANOVA did not reveal any signiﬁcant diﬀerence
between the groups [F (3, 32) = 0.25; P= 0.86)].
Serum ALT/AST following the eﬀect of Eth
pretreatment on PTZ-induced brief seizure model
The ANOVA analysis of data collected via spectropho-
tometry revealed no signiﬁcant diﬀerence for serum
ALT level between the groups [F (3, 31) = 2.11; P=
0.12)](Figure 3). Nevertheless, the Kruskal–Wallis ana-
lysis indicated a signiﬁcant diﬀerence between the
groups for AST (Figure 4)[H(3) = 21.20;P = < 0.001].
Moreover, the Tukey’s post-hoc analysis of the serum
AST level presented a signiﬁcant diﬀerence for PTZ
group, compared to the control (P < 0.5). Nevertheless,
no signiﬁcant diﬀerence was observed for the serum
AST level between the PTZ and Eth+PTZ groups
(P > 0.05; Figure 4).
NR1 mRNA expression following the eﬀect of Eth
pretreatment on PTZ-induced brief seizure model
The ANOVA analysis of data collected from Real-time
PCR presented a signiﬁcant diﬀerence between the
groups[F (3, 13) = 139.23; P < 0.001]. Furthermore,
Holm–Sidak post-hoc analysis revealed that the NR1
mRNA expression was decreased in the Eth and PTZ
groups, compared to the control group (P < 0.001).
Nevertheless, the NR1 mRNA expression was increased
in the coadministration Eth+PTZ group, compared to
the PTZ group (P < 0.001; Figure 5).
Discussion
The objective of the present study was to ﬁnd out
whether the low-dose Eth could ameliorate the PTZ-
induced amnesia in a brief seizure model. We also
aimed to ﬁnd a possible link between the events in
terms of alteration in the liver injury biochemical mar-
kers and the expression of NR1 subunit of NMDA
receptor using Real-time PCR in the hippocampus of
rats.
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The ﬁndings from the behavioral experiments
revealed that PTZ injection impaired the IA memory,
whereas the coadministration of Eth+PTZ improved
the impaired memory induced by PTZ. In addition,
in our study, we observed no change in locomotion as
measured by an open ﬁeld.
At the behavioral level and in accordance with the
results of our behavioral tests, in similar studies, the
application of PTZ revealed the impairment of IA
memory in mice [21,22]. The memory impairment
induced by PTZ in our study was along with
decreased NR1 mRNA expression, as seen in diﬀerent
seizure models [23]. Nevertheless, as reported pre-
viously, a single episode of seizure induced by PTZ
presented contradictory results on the memory [24].
Although there is no clear explanation for the dis-
crepancy, one possible suggestion for memory
improvement by PTZ may be related to the reward-
ing eﬀects of the subconvulsive dose of PTZ that has
the potential of memory enhancement in condition-
ing paradigms [25]. More interestingly, the coadmi-
nistration of Eth+PTZ in our experiments improved
Figure 1. Eﬀect of Eth pretreatment and the co-administration of Eth+PTZ on IA memory in the rat. The experiment consisted of
four groups of rats: Control, Eth (0.5 g/kg), PTZ (60 mg/kg) and Eth + PTZ, N = 9 rats per group. Eth was injected 6 days before
PTZ. The PTZ injection was carried out 30 min prior to the memory retrieval test. The data are shown as median±interquartile.++
+P < 0.001 and ***P < 0.001, compared to Control and PTZ groups, respectively.
Figure 2. Motor activity of rat in open-ﬁeld. The experiment consisted of four groups of rats: Control (c), Eth (0.5 g/kg), PTZ
(60 mg/kg) and Eth + PTZ, N = 9 rats per group. Eth was injected 6 days before PTZ. The rats were tested in an open ﬁeld after
the completion of memory test. The total distance that the rat traveled (cm) in 5 min was recorded. The data are shown as the
mean ±SEM.
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the PTZ-induced memory impairment; besides, no
signiﬁcant diﬀerence was observed between the Eth
+PTZ and control groups, indicating that Eth pre-
treatment improved the impaired memory by PTZ,
almost to the control level. It seems that since the
PTZ by itself impaired the IA memory, the improving
eﬀect observed in Eth+PTZ group may be related to
the Eth pretreatment.
While several studies have evaluated the nervous
system stimulatory role of low doses of Eth in various
Eth-elicited behaviors [26,27], high-dose Eth revealed
a decrease in the motor activity [8]. In the present
study using low-dose Eth, we observed no diﬀerence
in locomotion between the groups. In disagreement,
only in one study, the similar dose of Eth increased
locomotor activity on the accelerating rotarod [28].
We measured the locomotion in a spontaneous loco-
motion model. However, the discrepancy may be due
to other methodological factors, including the dura-
tion of Eth administration, and species of animals.
Considering that besides the direct eﬀects, the
indirect neurotoxic eﬀect of Eth may be exerted via
liver-brain axis, the transfer of neurodegenerating
toxic products across the blood–brain barrier can be
resulted in cognitive impairment [29]. Eth-induced
cognitive impairment can indirectly be monitored by
Figure 3. Eﬀect of Eth pretreatment on serum ALT (U/L) level. The experiment consisted of four groups of rats: Control, Eth (0.5
g/kg), PTZ (60 mg/kg) and Eth + PTZ. N = 9 rats per group. The data are shown as mean±SEM.
Figure 4. Eﬀect of Eth pretreatment on serum AST (U/L) level. The experiment consisted of four groups of rats: Control, Eth (0.5
g/kg), PTZ (60 mg/kg) and Eth + PTZ. N = 9 rats per group. The data are shown as mean±SEM. (*p < 0.05 compared to the
control group).
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measuring the liver biomarkers. Elevated levels of liver
enzymes, alanine aminotransferase (ALT), and aspar-
tate aminotransferase (AST) in blood are commonly
used in clinical practice as an indicator of Eth-induced
liver damage [30]. A few studies have considered the
eﬀects of Eth preconditioning on AST and ALT serum
levels. Nevertheless, Zheng et al. reported that Eth
pretreatment diminished the serum ALT and AST
level in hepatic ischemia/reperfusion injury [31]. To
further evaluate the toxic eﬀect of low-dose Eth on the
liver, in our study, no signiﬁcant diﬀerence was seen
for the serum ALT level in all groups; however, serum
AST level was elevated in PTZ and Eth+PTZ coadmi-
nistration groups. Since the elevated AST was
observed only in PTZ received animals, it seems that
PTZ, but not Eth pretreatment, may be resulted in
increased AST level.
It is strongly established that the beneﬁcial eﬀect of
EtOH-PC on the nervous system occurs via its neuro-
protective eﬀects [32]. In addition, the NMDA recep-
tors are involved in the neuroprotective eﬀect of
EtOH-PC [33]. Moreover, it is assumed that in pre-
conditioning, Eth modulates the NMDA receptors
[33] via theNR1 subunit of these receptors [17]. The
NMDA receptors are glutamate-dependent ion chan-
nels, which are crucial for learning andmemory as well
as neuronal communication [34]. While at the present
time there is no clear explanation and mechanism for
the acute and chronicversuslow-dose eﬀects of Eth on
NMDA subunits [35], among multiple promising
mechanisms mentioned either for its chronic or
acute events, the event may be best explained by the
neuroprotective mechanism. From this point of view,
Eth acting as an NMDA antagonist [36] and via
decreasing the NMDA receptor expression, conditions
the receptor, that is, the state referred as precondition-
ing [18]. The molecular ﬁndings of our study revealed
increased NR1 mRNA expression in the group that
received Eth+PTZ coadministration, while the NR1
mRNA expression was decreased after the PTZ per se.
Several studies support the involvement of GABAa
and NMDA receptor mechanisms in the behavioral
eﬀects of ethanol [37–42]. Considering our ﬁndings
that indicate the NR1 expression was decreased fol-
lowing Eth treatment in Eth group, and the molecular
ﬁndings that low-dose ethanol treatment (for 6 days)
upregulate the NDMA receptors [32], one may
hypothesize that the Eth pretreatment in Eth+PTZ
group, via an unknown mechanism, preconditions
the NMDA receptors and improves memory in the
coadministered group. Therefore, it seems that
further studies are required to unveil the exact recep-
tor mechanism(s) underlying the combinational
eﬀects of low-dose Eth and PTZ on memory.
However, such changes in mRNA expression may
be due to the acute adaptive mechanisms against Eth-
induced inhibition of NMDA [35]. Considering the
notion that the inhibition of excitotoxicity induced by
NMDA receptors results in neuroprotection via the
inhibition of Ca+ release [13], some studies revealed
the protective eﬀect of resultant EtOH-PC [18,32,35].
As aforementioned, one may suggest the idea that
relative expression of NR1 mRNA can be considered
as a probable molecular correlate for EtOH-PC.
Alternatively, among other possible mechanisms sta-
ted by few researchers, another proposed mechanisms
for the protective eﬀect of Eth in nervous system
disorders via NMDA receptors may be related to
Figure 5. Eﬀect of Eth pretreatment on the relative expression of NR1 subunit of NMDA receptor using RT-PCR. The experiment
consisted of four groups of rats: Control, Eth (0.5 g/kg), PTZ (60 mg/kg) and Eth + PTZ. N = 6–7 rats per group. The data are
shown as mean±SEM. ***P < 0.001 and +++P < 0.001, compared to control and PTZ groups, respectively.
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the ability of Eth in inhibiting the release of excitatory
amino acids, inhibition of glutamate receptor, and
removing the oxidizing agents [43,44]; though, con-
sidering the mRNA expression of NR1, as the mole-
cular substrate for EtOH-PC, apparently
contradictory ﬁndings were reported by several
authors. For example, Hardy reported no NR1
mRNA increment following chronic Eth treatment
[33]. In another study, chronic Eth application selec-
tively up-regulated the NMDA subunit gene expres-
sion in cultured media [45]. In disagreement with our
study, low-dose Eth treatment increased the phos-
phorylation of the NR1 subunit in the cerebral cortex
and hippocampus of rats [35]. Apart from the
observed results, the discrepancy seen between the
mentioned studies may relate to the dose, model,
and the duration of Eth administration.
Considering the neuroprotection hypothesis
(aforementioned), the observed eﬀects of Eth on the
NMDA receptor subunits may underlie the mechan-
isms that compensate for ethanol-induced inhibition
of NMDA receptors. From this perspective, Eth is
considered as an NMDA antagonist [46]. Since glu-
tamate is a putative and ubiquitous excitatory trans-
mitter, the inhibitory eﬀect of Eth on NMDA
receptors may be manifested in the early behavioral
eﬀects of Eth on locomotion [47].
This study has certain advantages and limitations.
The advantage(s) of our study were that we used
a 6-day pretreatment protocol, as routinely reported
by other researchers [32,48]; however, other research-
ers reported similar ﬁndings with a 2-day EtOH-PC
[32]. Moreover, we administered Eth i.p.
Pharmacokinetically, the eﬀect of nonoral Eth admin-
istration is less varied compared to the oral one [49]
and the adverse eﬀects of the intragastric Eth are
more serious than the i.p. one [50].Notably, in our
study, the low-dose Eth treatment caused no toler-
ance or dependence. This is supported by several
studies with similar results even after a 2-month Eth
treatment [51]. In contrast, our study’s limitation was
that we could not measure the plasma level of Eth
due to some technical problems.
Another point of consideration is that memory
impairment model induced by PTZ in the present
study does not necessarily relate to the PTZ-induced
seizures. We explained under the ‘Brief seizure assess-
ment’ subtitle in the Material and methods section, the
details for a brief seizure induction. Nevertheless, the
previous study has reported that gangliosides have no
anticonvulsive eﬀect in PTZ-administered rats, but
reveal an improving eﬀect on the PTZ-induced memory
impairment. Moreover, antagonizing the PTZ-induced
seizures by diazepam does not confer protection against
the PTZ-induced memory impairment [52].
In summary, this is the ﬁrst study to provide
evidence that the low-dose ethanol can ameliorate
the amnesia induced by a brief seizure model and
the presumable role of NMDA signaling in the pro-
cess. Better understanding of these mechanisms can
expand our knowledge on Eth action and may estab-
lish new strategies for the treatment of relevant ner-
vous system disorders, in particular, among those
suﬀering from seizure-related syndromes.
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